MediaPress Releases Archives Media Inquiries In the News Press Releases FEATURED PRESS RELEASE December 9, 2025Tris Pharma Announces FDA Acceptance of NDA for Once-Nightly, Low-Sodium Oxybate Product for Narcolepsy and Idiopathic Hypersomnia October 16, 2025Tris Pharma Announces Acceptance of New Review Article Highlighting Challenges of Treating Moderate-to-Severe Acute Pain with Currently Available Drugs August 28, 2025Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas June 12, 2025Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting May 1, 2025Tris Pharma to Unveil Positive Phase 3 Results Including a Strong Safety Profile Showcasing the Potential of Cebranopadol, an Investigational First-in-Class Dual-NMR Agonist for the Treatment of Pain, at the 2025 ASRA Annual Meeting
